NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has agreed to work with MD Anderson spinout ApoCell to make its ApoStream liquid biopsy technology available to biotech and pharmaceutical companies.

ApoStream is a platform for the detection, isolation, and capture of circulating tumor cells (or other rare cells), and does not require the use of labels or antibodies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.